Literature DB >> 17192896

Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration.

Yian Chen1, Bin Zheng, David H Robbins, David N Lewin, Kaidi Mikhitarian, Amanda Graham, Laurrie Rumpp, Tammy Glenn, William E Gillanders, David J Cole, Xinghua Lu, Brenda J Hoffman, Michael Mitas.   

Abstract

To augment cytological diagnosis of pancreatic ductal adenocarcinoma (PDAC) in tissue samples obtained by minimally invasive endoscopic ultrasound-guided fine needle aspiration, we investigated whether a small set of molecular markers could accurately distinguish PDAC from chronic pancreatitis (CP). Expression levels of 29 genes were first determined by quantitative real-time RT-PCR in a training set of tissues in which the final diagnosis was PDAC (n=20) or CP (n=10). Using receiver operator characteristic curve analysis, we determined that the single gene with the highest diagnostic accuracy for discrimination of CP vs. PDAC in the training study was urokinase plasminogen activator receptor (UPAR; AUC value = 0.895, 95% CI=0.728-0.976). In the set of test tissues (n=14), the accuracy of UPAR decreased to 79%. However, we observed that the addition of 6 genes (EPCAM2, MAL2, CEA5, CEA6, MSLN and TRIM29; referred to as the 6-gene classifier) to UPAR resulted in high accuracy in both training and testing sets. Excluding 3 samples (out of 44; 7%) for which results of the UPAR/6-gene classifier were "undefined," the accuracy of the UPAR/6-gene classifier was 100% in training samples (n=29), 92% in 12 test samples (p=0.004 that results were randomly generated; p=0.046 that the UPAR/6-gene classifier was comparable to UPAR alone; chi2 test), 100% in 3 samples for which the initial cytological diagnosis was "suspicious" and 98% (40/41) overall. Our results provide evidence that molecular marker expression data can be used to augment cytological analysis. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192896     DOI: 10.1002/ijc.22487

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

Review 1.  Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.

Authors:  Barbara Bournet; Marion Gayral; Jérôme Torrisani; Janick Selves; Pierre Cordelier; Louis Buscail
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 4.  Head mass in chronic pancreatitis: Inflammatory or malignant.

Authors:  Amit K Dutta; Ashok Chacko
Journal:  World J Gastrointest Endosc       Date:  2015-03-16

5.  TRIM29 suppresses TWIST1 and invasive breast cancer behavior.

Authors:  Lingbao Ai; Wan-Ju Kim; Merve Alpay; Ming Tang; Carolina E Pardo; Shigetsugu Hatakeyama; W Stratford May; Michael P Kladde; Coy D Heldermon; Erin M Siegel; Kevin D Brown
Journal:  Cancer Res       Date:  2014-06-20       Impact factor: 12.701

6.  MicroRNAs in pancreatic ductal adenocarcinoma.

Authors:  Jong Y Park; James Helm; Domenico Coppola; Donghwa Kim; Mokenge Malafa; Seung Joon Kim
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

7.  Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment.

Authors:  Michelle A Anderson; Dean E Brenner; James M Scheiman; Diane M Simeone; Nalina Singh; Matthew J Sikora; Lili Zhao; Amy N Mertens; James M Rae
Journal:  J Mol Diagn       Date:  2010-08-13       Impact factor: 5.568

8.  Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.

Authors:  Lily Yang; Hui Mao; Zehong Cao; Y Andrew Wang; Xianghong Peng; Xiaoxia Wang; Hari K Sajja; Liya Wang; Hongwei Duan; Chunchun Ni; Charles A Staley; William C Wood; Xiaohu Gao; Shuming Nie
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

9.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

10.  Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.

Authors:  Gee Young Lee; Wei Ping Qian; Liya Wang; Yongqiang Andrew Wang; Charles A Staley; Minati Satpathy; Shuming Nie; Hui Mao; Lily Yang
Journal:  ACS Nano       Date:  2013-03-12       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.